Simvastatin (sodium salt)
| 规格 | 价格 | 货期 | 数量 |
|---|---|---|---|
| 5mg | ¥2565.00 | 现货 | |
| 10mg | ¥3847.00 | 现货 | |
| 25mg | ¥7695.00 | 现货 |
特色产品
- 用于免疫印迹和质谱分析等后续操作
- 适用于30 KDa-130 KDa大小的蛋白
- 可将信号灵敏度提高100倍
- 同时保持稳定的特异性和分辨率
- 提供更高的转录效率并抑制免疫激活
- 使用5-moUTP和Cy5-utp修饰
产品描述
Ki: 0.12 nM
Simvastatin is a HMG-CoA reductase inhibitor.
HMG-CoA reductase has been found to be the rate-limiting enzyme in the cholesterol biosynthetic pathway and the target of the “statin” class of cholesterol-lowering drugs.
In vitro: Previous study found that simvastatin could inhibit the incorporation of 14C-acetate to 14C-sterol with an IC50 value of 15 nm in cultured Hep G2 cells. In addition, simvastatin was found to be a potent inhibitor of cholesterol synthesis in cultured liver cells, whereas pravastatin inhibited cholesterol synthesis in liver cells only after these cells had been digested by collagenase [1].
In vivo: Animal study showd that rats orally dosed with simvastatin had lower plasma cholesterol levels after 4 days of treatment. At the level of 0.02% of the diet, simvastatin lowered plasma cholesterol levels in rats by 64%. Moreove, in dogs, simvastatin at a daily oral dosage of 8 mg/kg lower levels of plasma cholesterol. At this dosage, simvastatin was slightly more potent than lovastatin and the levels of plasma cholesterol in these dogs returned to pretreatment levels after stopping the treatment [1].
Clinical trial: Previous clinical study found that both atorvastatin and simvastatin had significant PD reduction and RAL gain than placebo. Atorvastatin group showed greater mean PD reduction and mean RAL gain as compared to simvastatin group. Furthermore, atorvastatin group exhibited a significantly greater percentage of radiographic defect depth reduction as compared to simvastatin at 6 and 9 months [2].
References:
[1] Chao, Y. ,Chen, J.S.,Hunt, V.M., et al. Lowering of plasma cholesterol levels in animals by lovastatin and simvastatin. European Journal of Clinical Pharmacology 40, S11-S14 (1991).
[2] S Martande S, Kumari M, Pradeep AR, Pal Singh S, Kumar Suke D. nComparative evaluation of efficacy of subgingivally delivered 1.2% Atorvastatin and 1.2% Simvastatin in the treatment of intrabony defects in chronic periodontitis: a randomized controlled trial. J Dent Res Dent Clin Dent Prospects. 2017 Winter;11(1):18-25.
产品性质
| 物理外观 | A crystalline solid |
| CAS号 | 101314-97-0 |
| 分子式 | C25H41NaO6 |
| 分子量 | 460.59 |
| 小分子别名 | Simvastatin hydroxy acid sodium |
| 溶解度 | ≥28.85 mg/mL in DMSO; ≥23.05 mg/mL in EtOH; ≥5.47 mg/mL in H2O with ultrasonic |
| SMILES | CCC(C)(C)C(O[C@@H]1[C@H]([C@@H](CC[C@H](C[C@H](CC([O-])=O)O)O)[C@@H](C)C=C2)C2=C[C@H](C)C1)=O.[Na+] |
| 存储条件 | -20°C |
| 运输条件 | 蓝冰 |



沪公网安备 31011002003500